ABSTRACT
Correspondence to Dr Sara Monti, Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia 27100, Italy;sara.saramonti@gmail.com We thank Dr Conticini et al 1 for their comment on our previously published paper describing the course of COVID-19 in a cohort of patients treated with biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs).2 The authors commented on the low prevalence of subjects treated with bDMARDs in our cohort of patients affected by COVID-19;however, our paper actually described the course of severe acute respiratory coronavirus-2 (SARS-CoV-2) infection in the cohort of patients attending our biologic clinic rather than the opposite. Large, multicentre, national and international cohorts have been launched to actively recruit patients such as the Italian Society of Rheumatology–sponsored registry (COVID-19-RMD) or the European EULAR-COVID-19 Database.3 The results from these large cohorts are awaited to properly assess the incidence and prevalence of COVID-19 among rheumatological patients and the clinical implications on this susceptible population. The evaluation of the epidemiology of COVID-19 among patients with rheumatic diseases will need to take into account the potential impact that the use of immunomodulatory drugs may have both on the course of the infection and on the careful preventive behavioural changes that our patients affected by chronic conditions might have adopted to protect themselves during the pandemic.